Abstract: The present invention relates to antibodies, immunoglobulin constructs or immunoglobulin IgG4 fusion proteins whose in vivo half-lives are increased by the combination of (i) a modified IgG4 Fc region or FcRn binding domain thereof and (ii) a modified IgG4 hinge region sequence.

Abstract: The present invention provides an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80) and the antibody inhibits the binding of human IL-12 to human IL-12R ?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.

Abstract: The present invention provides humanized antibodies and binding domains thereof with anti-tumor activity. In particular the humanized antibodies have specific binding to and direct killing of human colon tumor cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumor models.

Abstract: The present disclosure provides an isolated or recombinant IL-23-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain specifically binds to IL-23 but does not significantly bind to an IL-12p40 subunit and does not significantly bind to an IL-23p19 subunit when they are not components of IL-23. The present disclosure also provides uses of the IL-23-binding protein.

Abstract: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-?, the dAb comprising an immunoglobulin heavy or light chain variable domain, comprising at least one complementarity determining region (CDR) having a sequence derived from a New World primate.

Abstract: The present invention provides an isolated specific binding member capable of binding a sialyltetraosyl carbohydrate and directly inducing cell death without the need for immune effector cells. Such a binding member may be an antibody or a part thereof. Also provided are the use of such binding members in medicine and nucleic acids encoding such binding members.

Abstract: The present invention provides a method of treating cancer in a subject wherein the cancer comprises mutated KRAS or BRAF genes. The method comprises administering to the subject an effective amount of an antibody or antigen binding fragment thereof wherein the antibody or antigen binding fragment thereof competes with SC104 for binding to the human colon cancer cell line Colo205.

Abstract: The invention relates to the use of a binding member which binds to LewisY and Lewisb haptens in the treatment of tumours and leukaemia. The binding member may be an antibody which binds to LewisY and Lewisb haptens and cancer cells and induces cells death.

Abstract: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF?, the dAb comprising an immunoglobulin heavy or light chain variable domain comprising at least one complementarity determining region (CDR) having a sequence derived from a New World primate.

Abstract: The present invention provides an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80) and the antibody inhibits the binding of human IL-12 to human IL-12R ?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.

Abstract: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-?, the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein the variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate.

Abstract: The present invention provides an isolated specific binding member capable of binding a sialyltetraosly carbohydrate and directly inducing cell death without the need for immune effector cells. Such a binding member may be an antibody or a part thereof. Also provided are the use of such binding members in medicine and nucleic acids encoding such binding members.

Abstract: The invention relates to the use of a binding member which binds to Lewisy and Lewisb haptens in the treatment of tumours and leukaemia. The binding member may be an antibody which binds to Lewisy and Lewisb haptens and cancer cells and induces cells death.

Abstract: The present invention provides a domain antibody construct which binds to human TNF-?, with the construct comprising: (a) a domain antibody (dAb) which binds to human TNF-?; (b) a modified hinge region sequence; (c) a human or primate heavy chain constant region sequence having a truncated CH1 domain of not more than 20 residues, wherein the modified hinge region sequence contains either a deletion or a single amino acid substitution of at least one cysteine residue which normally facilitates disulfide bond formation between heavy and light antibody chains.

Abstract: The present invention provides humanised antibodies and binding domains thereof with anti-tumour activity. In particular the humanised antibodies have specific binding to and direct killing of human colon tumour cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumour models.